Locations:
Search IconSearch
July 14, 2017/Cancer

Well-Differentiated Lipomatous Tumors: A Case Series (Video)

Soft tissue pathology service’s most common consult

In this case series, John Goldblum, MD, chairman of the Department of Pathology in Cleveland Clinic’s Robert J. Tomsich’s Pathology and Laboratory Medicine Institute and an expert in soft tissue tumor pathology, reviews three cases of soft tissue tumors. According to Dr. Goldblum, well-differentiated lipomatous tumors are the most common reason that clinicians consult the department’s soft tissue pathology service. “It’s a very common problem seen by all surgical pathologists,” he says, before offering an overview of Cleveland Clinic’s approach to identifying these legions through the lens of three typical cases.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

He illustrates how to distinguish among pleomorphic lipomas, well-differentiated liposarcomas (also known as atypical lipomatous tumors) and dedifferentiated liposarcomas. The first case is a 49-year-old male with an upper back mass, and Dr. Goldblum emphasizes that the multi-nucleated floret-like giant cells seen in the slide are suggestive of but not pathognomonic of pleomorphic lipomas.

The second case is a deep soft tissue mass from the thigh of a 65-year-old female. Dr. Goldblum notes the atypical hyperchromatic nuclei that lead him toward a diagnosis of well-differentiated liposarcoma. He also explains why he never looks for lipoblasts when examining a well-differentiated fatty tumor.

In this case series, John Goldblum, MD, chairman of the Department of Pathology in Cleveland Clinic’s Robert J. Tomsich’s Pathology and Laboratory Medicine Institute and an expert in soft tissue tumor pathology, reviews three cases of soft tissue tumors. According to Dr. Goldblum, well-differentiated lipomatous tumors are the most common reason that clinicians consult the department’s soft tissue pathology service. “It’s a very common problem seen by all surgical pathologists,” he says, before offering an overview of Cleveland Clinic’s approach to identifying these legions through the lens of three typical cases.

He illustrates how to distinguish among pleomorphic lipomas, well-differentiated liposarcomas (also known as atypical lipomatous tumors) and dedifferentiated liposarcomas. The first case is a 49-year-old male with an upper back mass, and Dr. Goldblum emphasizes that the multi-nucleated floret-like giant cells seen in the slide are suggestive of but not pathognomonic of pleomorphic lipomas.

Advertisement

The second case is a deep soft tissue mass from the thigh of a 65-year-old female. Dr. Goldblum notes the atypical hyperchromatic nuclei that lead him toward a diagnosis of well-differentiated liposarcoma. He also explains why he never bothers to identify lipoblasts when examining a well-differentiated fatty tumor.

In the final case, he examines a large retroperitoneal mass from an elderly patient and highlights the importance of examining the slide’s periphery in order to identify any well-differentiated liposarcomatous components. Find out why Dr. Goldblum argues that the type of spindle cell sarcoma is inconsequential in this case in the video below:

Pathology Insights: Well-Differentiated Lipomatous Tumors with John Goldblum, MD

The accurate diagnosis, grading and staging of benign and malignant soft tissue neoplasms, as well as mesenchymal neoplasms of the skin and parenchymal organs, can be challenging. Cleveland Clinic’s soft tissue pathology service, led by Karen Fritchie, MD, offers consultations on some of the most difficult cases in soft tissue pathology as well as a fellowship program and continuing medical education opportunities for practicing pathologists.

Advertisement

Related Articles

CAR T-cell therapy illustration
June 12, 2025/Cancer/News & Insight
First-Ever U.S. Trial of CAR T-Cell Therapy for Relapsed/Refractory AL Amyloidosis

Early results show patients experiencing deep and complete response

Genomic profiling
June 10, 2025/Cancer
Cleveland Clinic’s Hemato-Oncology Team Spearheads the Development of Guidelines for Genomic Profiling of MDS to Inform Allo-HCT

Inclusion of genomic profiling and risk factors recommended for treatment planning

scan showing cholangiocarcinoma
June 5, 2025/Cancer/News & Insight
Exploring Novel Therapeutic Avenues in Advanced Cholangiocarcinoma: Lessons from the EA2187 Trial

Collaborative research effort underscores the urgent need for effective second-line therapies in this rare, aggressive cancer

Anticoagulant sign
June 4, 2025/Cancer/News & Insight
Direct-Acting Oral Anticoagulants Safe for Patients with Brain Metastasis

Largest study to date comparing direct-acting oral anticoagulants to low-molecular-weight heparin

Squamous cell carcinoma
June 2, 2025/Cancer/News & Insight
Adjuvant Immunotherapy in High-Risk Cutaneous Squamous Cell Carcinoma

Pembrolizumab does not improve outcomes, but immunotherapy may still offer benefit

Photonic sensor
May 22, 2025/Cancer/News & Insight
Novel Partnership Aims to Advance ctDNA Testing in Non-Small Cell Lung Cancer

Cleveland Clinic, the University of Minnesota and University of Cambridge receive $1M grant to develop point-of-care biosensor for early detection and treatment personalization

gastroesophageal cancer illustration
May 20, 2025/Cancer/News & Insight
Roughly One-Third of Patients with Metastatic Gastroesophageal Cancer May be Eligible for New Targeted Therapy

Long-acting antiemetics and high-dose steroids key to minimizing acute nausea

Ad